Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Decreases By 6.1%

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) was the recipient of a significant decline in short interest in April. As of April 30th, there was short interest totalling 2,450,000 shares, a decline of 6.1% from the April 15th total of 2,610,000 shares. Currently, 3.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 985,300 shares, the short-interest ratio is currently 2.5 days.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Bank of America dropped their target price on shares of Integra LifeSciences from $42.00 to $26.00 and set an "underperform" rating for the company in a report on Tuesday, May 7th. StockNews.com cut Integra LifeSciences from a "buy" rating to a "hold" rating in a report on Monday. Citigroup raised Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 target price on the stock in a report on Wednesday, April 3rd. Truist Financial decreased their price objective on shares of Integra LifeSciences from $37.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday, May 7th. Finally, Morgan Stanley dropped their target price on shares of Integra LifeSciences from $37.00 to $24.00 and set an "underweight" rating for the company in a report on Tuesday, May 7th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Integra LifeSciences presently has a consensus rating of "Hold" and a consensus price target of $36.80.

Integra LifeSciences Trading Up 0.2 %

IART traded up $0.05 during trading on Friday, hitting $27.54. The company's stock had a trading volume of 835,428 shares, compared to its average volume of 845,034. Integra LifeSciences has a twelve month low of $22.36 and a twelve month high of $50.78. The stock has a market cap of $2.17 billion, a PE ratio of 54.76, a PEG ratio of 0.84 and a beta of 1.17. The firm's 50 day moving average price is $31.48 and its 200-day moving average price is $37.73. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The firm had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. During the same period in the prior year, the firm posted $0.74 earnings per share. The business's quarterly revenue was down 3.2% compared to the same quarter last year. On average, analysts expect that Integra LifeSciences will post 3.03 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently bought and sold shares of IART. Swiss National Bank raised its position in shares of Integra LifeSciences by 0.9% in the 3rd quarter. Swiss National Bank now owns 161,994 shares of the life sciences company's stock worth $6,187,000 after buying an additional 1,500 shares during the period. Cooke & Bieler LP raised its holdings in shares of Integra LifeSciences by 4.4% in the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company's stock worth $123,447,000 after purchasing an additional 120,410 shares during the period. Cardinal Capital Management lifted its stake in shares of Integra LifeSciences by 1.6% in the 4th quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company's stock valued at $962,000 after purchasing an additional 347 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Integra LifeSciences during the 3rd quarter worth about $43,034,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Integra LifeSciences during the 3rd quarter worth approximately $25,443,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.